DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effects of Long Term Macrolide Antibiotic Therapy in Patients With COPD

Information source: Royal Free and University College Medical School
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: COPD

Intervention: Erythromycin (Drug)

Phase: Phase 2/Phase 3

Status: Active, not recruiting

Sponsored by: Royal Free and University College Medical School

Official(s) and/or principal investigator(s):
Jadwiga A Wedzicha, MD, Principal Investigator, Affiliation: Royal Free and University College Medical School


The purpose of this study is to determine whether long term treatment with oral erythromycin is effective in the treatment of subjects with Chronic Obstructive Pulmonary Disease (COPD) by reducing the number of exacerbations and the degree of airway inflammation.

Clinical Details

Official title: Randomised Double Blind Placebo Controlled Trial of Effects of Long Term Low Dose Oral Erythromycin Therapy in Patients With Chronic Obstructive Pulmonary Disease

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome:

Exacerbation Frequency

Airway Inflammation

Secondary outcome:

Lung Function

Health Status

Exacerbation Recovery Time


Detailed description: COPD is characterised by persisting airway inflammation which leads to a progressive and irreversible deterioration in lung function with the eventual development of respiratory symptoms which may become disabling. Periodic episodes of worsening symptoms or exacerbations are a major cause of additional morbidity, mortality and health care utilization. Currently available therapies have limited efficacy in reducing airway inflammation or preventing exacerbations. Macrolides such as erythromycin have been shown to have potent anti-inflammatory effects in in vitro experiments and in other lung conditions such as cystic fibrosis and bronchiectasis as well as in open label studies in COPD. We hypothesised that long term therapy with oral erythromycin would reduce airway inflammation and reduce the frequency of exacerbations in patients with COPD. If these properties are demonstrated this therapy can have potentially important benefits if effective in this condition.


Minimum age: 40 Years. Maximum age: 90 Years. Gender(s): Both.


Inclusion Criteria:

- Clinical Diagnosis of COPD

- Clinically stable for 6 weeks

- Able to Swallow Tablets

Exclusion Criteria:

- Clinically significant respiratory disease other than COPD

- Women of child bearing age

- Patients receiving existing Medication which may interact adversely with trial drug

- History of clinically significant liver disease

Locations and Contacts

Royal Free Hospital, London, England NW3 1PF, United Kingdom
Additional Information

Starting date: April 2004
Last updated: September 2, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017